2022年美国成人青光眼患病率
该meta分析整合美国国家健康与营养调查、医保索赔、商业保险索赔、人群眼病研究及2022年人口估计数据,采用贝叶斯meta回归估计2022年美国18岁及以上人群青光眼患病率为1.62%,40岁及以上为2.56%,视力受损性青光眼患病率分别为0.57%和0.91%;黑人成人患病率高于白人成人,州和县水平估计有助于公共卫生规划。
要点
- 40岁及以上人群青光眼患病率2.56%,视力受损性青光眼患病率0.91%。
- 黑人成人青光眼患病率3.15%,高于白人成人的1.42%。
核心结论
- 该meta分析估计40岁及以上人群青光眼患病率为2.56%,略高于既往研究估计。
- 黑人个体受累比例过高。
- 州和县水平的患病率估计有助于指导公共卫生规划。
研究设计与样本
- 该meta分析数据来源于美国国家健康与营养调查(2005-2008)、联邦医疗保险按服务付费索赔(2019)、IBM MarketScan商业保险索赔(2016)、人群眼病研究(1985-2003)及美国人口普查局2022年人口估计。
- 通过PubMed检索1991至2016年发表的青光眼患病率人群研究。
- 采用贝叶斯meta回归方法按年龄、未区分性别/社会性别、种族和民族及美国县和州分层估计青光眼和视力受损性青光眼患病率。
- 主要结局为18岁及以上人群任何类型青光眼(开角或闭角)患病率及视力受损性青光眼(青光眼伴视野异常)患病率。
主要发现
- 18岁及以上人群青光眼患病率为1.62%(UI,1.33%-2.00%),40岁及以上人群为2.56%(UI,2.10%-3.16%)。
- 18岁及以上人群青光眼患病率从犹他州的1.11%(UI,0.89%-1.40%)到密西西比州的1.95%(UI,1.57%-2.39%)不等。
- 黑人成人患病率为3.15%(UI,2.32%-4.09%),白人成人为1.42%(UI,1.10%-1.85%),西班牙裔及其他所有种族和民族类别合并的成人患病率为1.56%(UI,1.13%-2.06%)。
关键数值与推荐
- 任何类型青光眼定义为开角或闭角型青光眼。
- 视力受损性青光眼定义为青光眼伴视野异常。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Glaucoma is the leading cause of irreversible blindness worldwide and, in the US, disproportionately affects people from racial and ethnic minority groups. Glaucoma prevalence has not been estimated for the US in more than a decade, and state- and county-level estimates are not available. OBJECTIVE: To estimate glaucoma and vision-affecting glaucoma prevalence by demographic factors and US state and county for the Centers for Disease Control and Prevention's Vision and Eye Health Surveillance System (VEHSS). DATA SOURCES: This meta-analysis used data from the National Health and Nutrition Examination Survey (2005-2008), Medicare fee-for-service claims (2019), IBM MarketScan commercial insurance claims (2016), population-based studies of eye disease (1985-2003), and 2022 population estimates from the US Census Bureau. STUDY SELECTION: PubMed was searched for population-based studies of glaucoma prevalence published between 1991 and 2016. DATA EXTRACTION AND SYNTHESIS: Bayesian meta-regression methods were used to estimate the prevalence of glaucoma and vision-affecting glaucoma stratified by age, undifferentiated sex/gender (a measure that captures an unclear mix of aspects of sex and or gender), race and ethnicity, and US county and state. MAIN OUTCOMES AND MEASURES: Prevalence of any type of glaucoma (open or closed angle) among people 18 years or older and vision-affecting glaucoma, defined as glaucoma and a visual field abnormality. RESULTS: For 2022, an estimated 4.22 million people (95% uncertainty interval [UI], 3.46 million to 5.23 million) in the US were living with glaucoma, with a prevalence of 1.62% (UI, 1.33%-2.00%) among people 18 years or older and 2.56% (UI, 2.10%-3.16%) among people 40 years or older. An estimated 1.49 million people (UI, 1.17 million to 1.90 million) were living with vision-affecting glaucoma, with a prevalence of 0.57% (UI, 0.45%-0.73%) among people 18 years or older and 0.91% (UI, 0.71%-1.16%) among people 40 years or older. Prevalence of glaucoma among people 18 years or older ranged from 1.11% (UI, 0.89%-1.40%) in Utah to 1.95% (UI, 1.57%-2.39%) in Mississippi. Black adults had a prevalence of 3.15% (UI, 2.32%-4.09%) compared with 1.42% (UI, 1.10%-1.85%) among White adults; adults in the Hispanic and all other racial and ethnic categories combined had a prevalence of 1.56% (UI, 1.13%-2.06%). CONCLUSIONS AND RELEVANCE: This meta-analysis found that an estimated 2.56% of people 40 years or older have glaucoma, slightly more than estimated by previous studies. Black individuals are disproportionately affected. Prevalence estimates at the state and county level can help guide public health planning.
引用
- Ehrlich JR, Burke-Conte Z, Wittenborn JS, et al. Prevalence of Glaucoma Among US Adults in 2022. JAMA Ophthalmol. 2024. PMID: 39418040. doi:10.1001/jamaophthalmol.2024.3884
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。